<DOC>
	<DOCNO>NCT02091921</DOCNO>
	<brief_summary>Critical Limb Ischemia ( CLI ) define limb pain occur rest , impend limb loss cause severe compromise blood flow affect extremity . CLI major cause death disability ( secondary myocardial infarction , stroke amputation ) . The mortality patient CLI approach 13-25 % 50 % one five year respectively . High on-treatment platelet reactivity ( HPR ) patient treat aspirin clopidogrel associate increase risk recurrent cardiovascular event percutaneous coronary intervention coronary syndrome . Preliminary study suggest prevalence HPR patient critical limb ischemia treat aspirin clopidogrel high 78.5 % . In patient coronary artery disease ticagrelor overcome non-responsiveness clopidogrel . However , antiplatelet effect ticagrelor patient critical limb ischemia unknown .</brief_summary>
	<brief_title>Switch Ticagrelor Critical Limb Ischemia Anti-platelet Study</brief_title>
	<detailed_description>Study Aim : This pilot study aim investigate platelet function switch clopidogrel ticagrelor patient critical limb ischemia . Fifty patient diagnosis CLI ( Rutherford class IV-VI ) treat clopidogrel 75 mg aspirin 81 mg daily test inhibition platelet aggregation use VerifyNow P2Y12 VASP assay 6±1 hour daily clopidogrel dose . All patient switch clopidogrel ticagrelor 90 mg twice daily two week VerifyNow VASP platelet reactivity assays repeat , sample collect 6±1 hour last ticagrelor dose . For exploratory analysis , patient divide two group base P2Y12 reaction unit ( PRU ) : Group 1 . High treatment platelet reactivity clopidogrel ( HPR ) , define P2Y12 reaction unit ( PRU ) ≥235 Group 2 . Appropriate platelet inhibition clopidogrel ( API ) , define P2Y12 reaction unit ( PRU ) &lt; 235 .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Patients diagnosis CLI ( Rutherford class IV , V VI ) continuous dual antiplatelet therapy aspirin 81 mg clopidogrel 75 mg daily least 14+2 day . Chronic use nonsteroidal antiinflammatory drug , thrombocytopenia ( platelet count &lt; 100 × 103/μl ) , hemoglobin &lt; 10 g/dL , use oral anticoagulant ( warfarin ) low molecular weight heparin within 14 day , GPIIb/IIIa inhibitor , fibrinolytic drug within 30 day . Pregnancy , &lt; 18 &gt; 80 year age , current smoking ( &gt; 1 pack per day ) , concomitant therapy strong cytochrome P450 3A inhibitor inducer within 14 day , concomitant antithrombotic therapy aspirin within 14 day , hypercoaguable state . History medication noncompliance , drug alcohol abuse within 2 year . Acute coronary syndrome coronary drugeluting stenting within 1 year . Peripheral vascular revascularization procedure ( surgical endovascular ) and/or amputation within one month . Contraindications ticagrelor include : hypersensitivity ticagrelor excipients , Active pathological bleeding , History intracranial hemorrhage Severe hepatic impairment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Critical Limb Ischemia , ticagrelor , Brilinta</keyword>
</DOC>